English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsIpcalaboratories

    Jump to
    • Aim is to prevent rampant use of antibiotics: P Lilladher

      Aim is to prevent rampant use of antibiotics: P Lilladher

      Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.

    • Indore facility to start production in 2 months: Ipca Labs

      Indore facility to start production in 2 months: Ipca Labs

      AK Jain, ED, Ipca Labs says the company's pain management segment is doing ver well and it has leadership in rheumatoid arthritis with substantial market share. The company's Indore facility will start production in 2 months.

    • Eyeing 18-20% growth in domestic market in FY13: Ipca Labs

      Eyeing 18-20% growth in domestic market in FY13: Ipca Labs

      Exectuive director of Ipca Labs AK Jain told CNBC-TV18 that Ipca Lanbs aims to grow by 18-20% in the domestic market in FY13.

    • Ipca Labs hopes to achieve 18-20% growth for FY12

      Ipca Labs hopes to achieve 18-20% growth for FY12

      AK Jain, the executive director of Ipca Labs, in an interview on CNBC-TV18, talks about the latest happenings in the company and sector.

    • Expect USFDA nod for Indore unit in three months: Ipca Labs

      Expect USFDA nod for Indore unit in three months: Ipca Labs

      In an interview with CNBC-TV18, AK Jain, ED of Ipca Labs said, "We are waiting for the US FDA to inspect our SEZ Indore plant. This product will be produced there so, till the time we get the approval for the plant we will not be able to take the commercial production of this product."

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347